HPV16 E6 Seropositivity Among Cancer-free Men with Oral, Anal or Genital HPV16 Infection

Overview

Journal Papillomavirus Res

Specialties Microbiology
Oncology

Date 2017 Feb 28

PMID 28239675

Citations 5

Authors

Daniel C Beachler

Tim Waterboer

Christine M Pierce Campbell

Donna J Ingles

Krystle A Lang Kuhs

Alan G Nyitray

Allan Hildesheim

Michael Pawlita

Aimee R Kreimer

Anna R Giuliano

Affiliations

Soon will be listed here.

Abstract

Antibodies against the Human papillomavirus 16 (HPV16) E6 oncoprotein appear years prior to clinical diagnosis of anal and oropharyngeal cancer, but whether they develop around the time of HPV infection is unclear. Serum samples from 173 cancer-free men from the Human Papillomavirus Infection in Men (HIM) Study were tested for HPV antibodies and DNA. HPV16 E6 seropositivity was low among men with oral HPV16-infection (1/28; 3.6%, 95%CI=0.0%-18.4%), anal HPV16-infection (1/61; 1.6%, 95%CI=0.0%-8.8%), and 24-month persistent genital HPV16-infection (1/84; 1.2%, 0.0-6.5%). This suggests E6 seroconversion may not occur around the time of oral, anal, or genital HPV16 acquisition.

Citing Articles

High levels of HPV16-L1 antibody but not HPV16 DNA load or integration predict oropharyngeal patient outcome: The Papillophar study.

Pretet J, Dalstein V, Touze A, Beby-Defaux A, Soussan P, Jacquin E Clin Exp Med. 2022; 23(1):87-96.

PMID: 35199231 DOI: 10.1007/s10238-022-00796-2.

Transmission and clearance of human papillomavirus infection in the oral cavity and its role in oropharyngeal carcinoma - A review.

Wierzbicka M, San Giorgi M, Dikkers F Rev Med Virol. 2022; 33(1):e2337.

PMID: 35194874 PMC: 10078185. DOI: 10.1002/rmv.2337.

Long-term Persistence of Oral HPV Over 7 Years of Follow-up.

DSouza G, Clemens G, Strickler H, Wiley D, Troy T, Struijk L JNCI Cancer Spectr. 2020; 4(5):pkaa047.

PMID: 33225205 PMC: 7667996. DOI: 10.1093/jncics/pkaa047.

[HPV - A different view on Head and Neck Cancer].

Wittekindt C, Wagner S, Sharma S, Wurdemann N, Knuth J, Reder H Laryngorhinootologie. 2018; 97(S 01):S48-S113.

PMID: 29905354 PMC: 6540966. DOI: 10.1055/s-0043-121596.

Understanding personal risk of oropharyngeal cancer: risk-groups for oncogenic oral HPV infection and oropharyngeal cancer.

DSouza G, McNeel T, Fakhry C Ann Oncol. 2017; 28(12):3065-3069.

PMID: 29059337 PMC: 5834136. DOI: 10.1093/annonc/mdx535.

References

Nyitray A, Carvalho da Silva R, Baggio M, Lu B, Smith D, Abrahamsen M . Age-specific prevalence of and risk factors for anal human papillomavirus (HPV) among men who have sex with women and men who have sex with men: the HPV in men (HIM) study. J Infect Dis. 2010; 203(1):49-57. PMC: 3086435. DOI: 10.1093/infdis/jiq021. View

Kreimer A, Brennan P, Lang Kuhs K, Waterboer T, Clifford G, Franceschi S . Human papillomavirus antibodies and future risk of anogenital cancer: a nested case-control study in the European prospective investigation into cancer and nutrition study. J Clin Oncol. 2015; 33(8):877-84. PMC: 4348636. DOI: 10.1200/JCO.2014.57.8435. View

Giuliano A, Lazcano-Ponce E, Villa L, Flores R, Salmeron J, Lee J . The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States. Cancer Epidemiol Biomarkers Prev. 2008; 17(8):2036-43. PMC: 3471778. DOI: 10.1158/1055-9965.EPI-08-0151. View

Lang Kuhs K, Pawlita M, Gibson S, Schmitt N, Trivedi S, Argiris A . Characterization of human papillomavirus antibodies in individuals with head and neck cancer. Cancer Epidemiol. 2016; 42:46-52. PMC: 4910878. DOI: 10.1016/j.canep.2016.03.003. View

Nyitray A, Chang M, Villa L, Carvalho da Silva R, Baggio M, Abrahamsen M . The natural history of genital human papillomavirus among HIV-negative men having sex with men and men having sex with women. J Infect Dis. 2015; 212(2):202-12. PMC: 4565999. DOI: 10.1093/infdis/jiv061. View

Beachler D, DSouza G, Sugar E, Xiao W, Gillison M . Natural history of anal vs oral HPV infection in HIV-infected men and women. J Infect Dis. 2013; 208(2):330-9. PMC: 3685232. DOI: 10.1093/infdis/jit170. View

Chaturvedi A, Engels E, Pfeiffer R, Hernandez B, Xiao W, Kim E . Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011; 29(32):4294-301. PMC: 3221528. DOI: 10.1200/JCO.2011.36.4596. View

Pierce Campbell C, Kreimer A, Lin H, Fulp W, OKeefe M, Ingles D . Long-term persistence of oral human papillomavirus type 16: the HPV Infection in Men (HIM) study. Cancer Prev Res (Phila). 2015; 8(3):190-6. PMC: 4355174. DOI: 10.1158/1940-6207.CAPR-14-0296. View

Carter J, Koutsky L, Hughes J, Lee S, Kuypers J, Kiviat N . Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis. 2000; 181(6):1911-9. DOI: 10.1086/315498. View

10.

Bertisch B, Franceschi S, Lise M, Vernazza P, Keiser O, Schoni-Affolter F . Risk factors for anal cancer in persons infected with HIV: a nested case-control study in the Swiss HIV Cohort Study. Am J Epidemiol. 2013; 178(6):877-84. DOI: 10.1093/aje/kwt153. View

11.

Gillison M, Broutian T, Pickard R, Tong Z, Xiao W, Kahle L . Prevalence of oral HPV infection in the United States, 2009-2010. JAMA. 2012; 307(7):693-703. PMC: 5790188. DOI: 10.1001/jama.2012.101. View

12.

Lang Kuhs K, Anantharaman D, Waterboer T, Johansson M, Brennan P, Michel A . Human Papillomavirus 16 E6 Antibodies in Individuals without Diagnosed Cancer: A Pooled Analysis. Cancer Epidemiol Biomarkers Prev. 2015; 24(4):683-9. PMC: 4383678. DOI: 10.1158/1055-9965.EPI-14-1217. View

13.

Tommasino M . The human papillomavirus family and its role in carcinogenesis. Semin Cancer Biol. 2013; 26:13-21. DOI: 10.1016/j.semcancer.2013.11.002. View

14.

Waterboer T, Sehr P, Pawlita M . Suppression of non-specific binding in serological Luminex assays. J Immunol Methods. 2006; 309(1-2):200-4. DOI: 10.1016/j.jim.2005.11.008. View

15.

Sitas F, Egger S, Urban M, Taylor P, Abnet C, Boffetta P . InterSCOPE study: Associations between esophageal squamous cell carcinoma and human papillomavirus serological markers. J Natl Cancer Inst. 2012; 104(2):147-58. PMC: 3260131. DOI: 10.1093/jnci/djr499. View

16.

Kreimer A, Johansson M, Waterboer T, Kaaks R, Chang-Claude J, Drogen D . Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol. 2013; 31(21):2708-15. PMC: 3709056. DOI: 10.1200/JCO.2012.47.2738. View

17.

Kreimer A, Pierce Campbell C, Lin H, Fulp W, Papenfuss M, Abrahamsen M . Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study. Lancet. 2013; 382(9895):877-87. PMC: 3904652. DOI: 10.1016/S0140-6736(13)60809-0. View